15335928Abatacept in Immune Checkpoint Inhibitor MyocarditisATRIUMRecruitingMyocarditis Acute, cancerDrug: abatacept plus, drug: placebo3United States24338269A Study of Atezolizumab in Combination with Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor TreatmentCONTACT-03Active, not recruitingCarcinoma, renal cellDrug: atezolizumab, drug: cabozantinib3United States, Argentina, Australia, Canada, Denmark, France, Germany, Greece, Italy, Japan, Korea, Poland, Russian Federation, Russian Federation, Spain, United Kingdom32654587Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients with Advanced NSCLC After Failure of Immune Checkpoint InhibitorATALANTE 1Active, not recruitingNon-small-cell lung cancerDrug: OSE2101, drug: docetaxel, drug: pemetrexed3United States, Czechia, France, Germany, Hungary, Israel, Italy, Poland, Spain, United Kingdom44987203Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaNARecruitingRenal cell carcinomaDrug: tivozanib, drug: nivolumab3United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Italy, Mexico, Poland, Portugal, Spain, United Kingdom53469960Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-Small Lung CancerDICIPLEActive, not recruitingNon-small-cell lung cancer metastaticDrug: ipilimumab, drug: nivolumab3France64590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerINTERLINK-1Active, not recruitingSquamous cell carcinoma of the head and neckDrug: monalizumab, drug: cetuximabPhase 3United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Italy, Japan, Korea, Netherlands, Philippines, Portugal, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom75106335A Study to Evaluate Camrelizumab Combined with Famitinib as Subsequent Therapy in Patients With Advanced NSCLCNARecruitingAdvanced NSCLCDrug: camrelizumab + famitinib, drug: famitinib, drug: docetaxel3China84059887Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]BUDDYRecruitingLung neoplasm MalignantDrug: atezolizumab injection (Tecentriq)4Korea93427827PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaPACIFIC-NPCRecruitingNasopharyngeal neoplasmsDrug: camrelizumab3China104907370PD-1 Blockade Combined with De-intensification Radical Chemoradiotherapy in Nasopharyngeal CarcinomaTIRARecruitingNasopharyngeal carcinomaDrug: PD-1 blocking antibody, drug: gemcitabine, drug: cisplatin (80 mg/m2), drug: cisplatin (100 mg/m2), radiation: intensity-modulated radiotherapy3China114334759Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural MesotheliomaDREAM3RRecruitingMesothelioma, pleural mesothelioma, malignant pleural mesotheliomaDrug: durvalumab, drug: standard chemotherapy, drug: ipilimumab and nivolumab3United States, Australia, New Zealand124799249Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)PRESERVE 2Active, not recruitingTriple-negative breast cancer (TNBC), breast cancerDrug: trilaciclib, drug: placebo, drug: gemcitabine, drug: carboplatin3United States, Australia, Bulgaria, China, France, Georgia, Moldova, Poland, Russian Federation, Serbia, Spain, Ukraine132973789Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent with Standard of Care Therapies for Treatment of Stage 4 Non-Small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)NAActive, not recruitingNon-small-cell lung cancer (NSCLC)Device: NovoTTF-200T, drug: immune checkpoint inhibitors or docetaxel3United States, Austria, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Hong Kong, Italy, Netherlands, Poland, Serbia, Spain, Switzerland